Skip to main content
Top
Published in: BMC Neurology 1/2020

Open Access 01-12-2020 | Magnetic Resonance Imaging | Research article

Blood-brain barrier integrity of stroke patients presenting in an extended time window

Authors: Jarrhett Butler, Parisa Heidari, Sarah Blayney, Emi Hitomi, Marie Luby, Richard Leigh

Published in: BMC Neurology | Issue 1/2020

Login to get access

Abstract

Background

Current guidelines limit thrombolytic treatment of stroke to those patients who present within 4.5 h to minimize the risk of hemorrhagic complications. Risk of hemorrhage increases with increasing blood-brain barrier (BBB) disruption. This study aimed to determine, in a cohort of patients presenting outside of an IV-tPA treatment window, whether disruption of the BBB is time dependent, and what proportion of patients could be safely treated.

Methods

We analyzed untreated stroke patients, seen between 2011 and 2015, who had MRI studies in the time window of 4 to 24 h from symptoms onset. Permeability of the BBB was measured within the ischemic tissue using an application of dynamic susceptibility contrast imaging. Patients were dichotomized into two groups based on a 20% threshold of BBB disruption and compared using logistic regression.

Results

Of the 222 patients included in the final analysis, over half, 129 (58%), had preserved BBB integrity below the 20% threshold. There was no relationship between time imaged after symptom onset and the amount of BBB disruption (p = 0.138) across the population; BBB disruption varied widely.

Conclusions

Estimating BBB integrity may help to expand the treatment window for stroke patients by identifying those individuals for whom thrombolytic therapy can be considered.
Literature
1.
go back to reference The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N.Engl.J.Med. 1995;333(24):1581–7.CrossRef The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N.Engl.J.Med. 1995;333(24):1581–7.CrossRef
2.
go back to reference Hacke W, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N.Engl.J.Med. 2008;359(13):1317–29.CrossRef Hacke W, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N.Engl.J.Med. 2008;359(13):1317–29.CrossRef
3.
go back to reference Powers WJ, et al. 2018 guidelines for the early Management of Patients with Acute Ischemic Stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49(3):e46–e110.CrossRef Powers WJ, et al. 2018 guidelines for the early Management of Patients with Acute Ischemic Stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49(3):e46–e110.CrossRef
4.
go back to reference Demaerschalk BM, et al. Scientific rationale for the inclusion and exclusion criteria for intravenous Alteplase in acute ischemic stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2016;47(2):581–641.CrossRef Demaerschalk BM, et al. Scientific rationale for the inclusion and exclusion criteria for intravenous Alteplase in acute ischemic stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2016;47(2):581–641.CrossRef
6.
go back to reference Hacke W, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian acute stroke study investigators. Lancet. 1998;352(9136):1245–51.CrossRef Hacke W, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian acute stroke study investigators. Lancet. 1998;352(9136):1245–51.CrossRef
7.
go back to reference Thomalla G, et al. Two tales: hemorrhagic transformation but not parenchymal hemorrhage after thrombolysis is related to severity and duration of ischemia: MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours. Stroke. 2007;38(2):313–8.CrossRef Thomalla G, et al. Two tales: hemorrhagic transformation but not parenchymal hemorrhage after thrombolysis is related to severity and duration of ischemia: MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours. Stroke. 2007;38(2):313–8.CrossRef
8.
go back to reference Simpkins AN, et al. Identification of reversible disruption of the human blood-brain barrier following acute ischemia. Stroke. 2016;47(9):2405–8.CrossRef Simpkins AN, et al. Identification of reversible disruption of the human blood-brain barrier following acute ischemia. Stroke. 2016;47(9):2405–8.CrossRef
9.
go back to reference Leigh R, et al. Pretreatment blood-brain barrier damage and post-treatment intracranial hemorrhage in patients receiving intravenous tissue-type plasminogen activator. Stroke. 2014;45(7):2030–5.CrossRef Leigh R, et al. Pretreatment blood-brain barrier damage and post-treatment intracranial hemorrhage in patients receiving intravenous tissue-type plasminogen activator. Stroke. 2014;45(7):2030–5.CrossRef
10.
go back to reference Leigh R, et al. Pretreatment blood-brain barrier disruption and post-endovascular intracranial hemorrhage. Neurology. 2016;87(3):263–9.CrossRef Leigh R, et al. Pretreatment blood-brain barrier disruption and post-endovascular intracranial hemorrhage. Neurology. 2016;87(3):263–9.CrossRef
11.
go back to reference Bang OY, et al. Prediction of hemorrhagic transformation after recanalization therapy using T2*-permeability magnetic resonance imaging. Ann.Neurol. 2007;62(2):170–6.CrossRef Bang OY, et al. Prediction of hemorrhagic transformation after recanalization therapy using T2*-permeability magnetic resonance imaging. Ann.Neurol. 2007;62(2):170–6.CrossRef
12.
go back to reference Nael K, et al. Multiparametric magnetic resonance imaging for prediction of parenchymal hemorrhage in acute ischemic stroke after reperfusion therapy. Stroke. 2017;48(3):664–70.CrossRef Nael K, et al. Multiparametric magnetic resonance imaging for prediction of parenchymal hemorrhage in acute ischemic stroke after reperfusion therapy. Stroke. 2017;48(3):664–70.CrossRef
14.
go back to reference Ma H, et al. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke. N Engl J Med. 2019;380(19):1795–803.CrossRef Ma H, et al. Thrombolysis guided by perfusion imaging up to 9 hours after onset of stroke. N Engl J Med. 2019;380(19):1795–803.CrossRef
16.
go back to reference Zaharchuk G. Theoretical basis of hemodynamic MR imaging techniques to measure cerebral blood volume, cerebral blood flow, and permeability. AJNR Am. J. Neuroradiol. 2007;28(10):1850–8.CrossRef Zaharchuk G. Theoretical basis of hemodynamic MR imaging techniques to measure cerebral blood volume, cerebral blood flow, and permeability. AJNR Am. J. Neuroradiol. 2007;28(10):1850–8.CrossRef
17.
go back to reference Boxerman JL, Schmainda KM, Weisskoff RM. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol. 2006;27(4):859–67.PubMed Boxerman JL, Schmainda KM, Weisskoff RM. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol. 2006;27(4):859–67.PubMed
18.
go back to reference Leigh R, et al. Arrival Time Correction for Dynamic Susceptibility Contrast MR Permeability Imaging in Stroke Patients. PLoS One. 2012;7(12):e52656.CrossRef Leigh R, et al. Arrival Time Correction for Dynamic Susceptibility Contrast MR Permeability Imaging in Stroke Patients. PLoS One. 2012;7(12):e52656.CrossRef
19.
go back to reference Wouters A, et al. A comparison of relative time to peak and Tmax for mismatch-based patient selection. Front Neurol. 2017;8:539.CrossRef Wouters A, et al. A comparison of relative time to peak and Tmax for mismatch-based patient selection. Front Neurol. 2017;8:539.CrossRef
20.
go back to reference Zaro-Weber O, et al. Maps of time to maximum and time to peak for mismatch definition in clinical stroke studies validated with positron emission tomography. Stroke. 2010;41(12):2817–21.CrossRef Zaro-Weber O, et al. Maps of time to maximum and time to peak for mismatch definition in clinical stroke studies validated with positron emission tomography. Stroke. 2010;41(12):2817–21.CrossRef
21.
go back to reference Albers GW, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med. 2018;378(8):708–18.CrossRef Albers GW, et al. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. N Engl J Med. 2018;378(8):708–18.CrossRef
22.
go back to reference Nogueira RG, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018;378(1):11–21.CrossRef Nogueira RG, et al. Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018;378(1):11–21.CrossRef
23.
go back to reference Schwamm LH, et al. Intravenous thrombolysis in unwitnessed stroke onset: MR WITNESS trial results. Ann Neurol. 2018;83(5):980–93.CrossRef Schwamm LH, et al. Intravenous thrombolysis in unwitnessed stroke onset: MR WITNESS trial results. Ann Neurol. 2018;83(5):980–93.CrossRef
24.
go back to reference Thomalla G, et al. MRI-guided thrombolysis for stroke with unknown time of onset. N Engl J Med. 2018;379(7):611–22.CrossRef Thomalla G, et al. MRI-guided thrombolysis for stroke with unknown time of onset. N Engl J Med. 2018;379(7):611–22.CrossRef
25.
go back to reference Farrall AJ, Wardlaw JM. Blood-brain barrier: ageing and microvascular disease--systematic review and meta-analysis. Neurobiol Aging. 2009;30(3):337–52.CrossRef Farrall AJ, Wardlaw JM. Blood-brain barrier: ageing and microvascular disease--systematic review and meta-analysis. Neurobiol Aging. 2009;30(3):337–52.CrossRef
26.
go back to reference Sandoval KE, Witt KA. Blood-brain barrier tight junction permeability and ischemic stroke. Neurobiol Dis. 2008;32(2):200–19.CrossRef Sandoval KE, Witt KA. Blood-brain barrier tight junction permeability and ischemic stroke. Neurobiol Dis. 2008;32(2):200–19.CrossRef
27.
go back to reference Hacke W, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363(9411):768–74.CrossRef Hacke W, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363(9411):768–74.CrossRef
28.
go back to reference Lees KR, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375(9727):1695–703.CrossRef Lees KR, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375(9727):1695–703.CrossRef
Metadata
Title
Blood-brain barrier integrity of stroke patients presenting in an extended time window
Authors
Jarrhett Butler
Parisa Heidari
Sarah Blayney
Emi Hitomi
Marie Luby
Richard Leigh
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2020
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-020-01634-2

Other articles of this Issue 1/2020

BMC Neurology 1/2020 Go to the issue